Analyst Price Target Update on LDR Holding Corporation (NASDAQ:LDRH)

LDR Holding Corporation (NASDAQ:LDRH): 8 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $33.75 in LDR Holding Corporation (NASDAQ:LDRH). However, the stock price could fluctuate by $ 4.95 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $40 price target with the lower price estimate is calculated at $27

Many analysts have stated their opinion on the company shares. Equity Analysts at the Barclays downgrades the rating on LDR Holding Corporation (NASDAQ:LDRH). The brokerage firm has issued a Equal-weight rating on the shares. The shares were previously rated Overweight. The Analysts at the ratings agency raises the price target from $27 per share to $37 per share. The rating by the firm was issued on June 10, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Richard Patrick, officer (EVP, European Sales, Medical) of Ldr Holding Corp, had unloaded 25,000 shares at an average price of $27.6 in a transaction dated on April 15, 2016. The total value of the transaction was worth $690,000.

LDR Holding Corporation (NASDAQ:LDRH) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.12 points or 0.32% at $36.86 with 1,551,078 shares getting traded. Post opening the session at $36.95, the shares hit an intraday low of $36.83 and an intraday high of $37.02 and the price was in this range throughout the day. The company has a market cap of $1,078 million and the number of outstanding shares have been calculated to be 29,232,859 shares. The 52-week high of LDR Holding Corporation (NASDAQ:LDRH) is $47.12 and the 52-week low is $16.33.

LDR Holding Corporation is a global medical device company. The Company is focused on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Companys primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine. The Companys VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Companys Mobi non-fusion platform is highlighted by Mobi-C, a cervical disc replacement device with a patented mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.